Keystone Symposia Conference | Inositide Signaling in Pharmacology and Disease

Meeting Program

To view program in "24 hour" time (international) click here.

Sunday, February 13
3:00 - 7:30 PM	Registration	Longs Peak Foyer
6:30 - 7:30 PM	Refreshments	Longs Peak Foyer
7:30 - 9:30 PM	Keynote Session (Joint) Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Longs/Grays Peak
	R.H. Michell, University of Birmingham, UK Evolution of the Diverse Biological Roles of Inositols
	Lewis C. Cantley, Harvard Medical School, USA The Role of Phosphoinositides in Human Disease
Monday, February 14
7:00 - 8:00 AM	Breakfast	Quandary Peak
8:00 - 11:00 AM	Phosphoinositide 3-Kinases Signaling in Disease: Class 1 PI3Ks (Joint) Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Longs/Grays Peak
	Bart Vanhaesebroeck, Barts & The London School of Medicine, UK Role of Different PI 3-Kinase Isoforms
	Roger L. Williams, Centre for Protein Engineering, UK Structural Insights into PI3K Isoform Signaling
	Len R. Stephens, Babraham Institute, UK Isoform-Selectivity Amongst Class I PI3K Isoforms
	Short Talk(s) to be Chosen from Abstracts,
	Ana Clara Carrera, Centro Nacional Biotechnologia/CSIC, Spain PI3K Isoforms in Human Disease
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:00 AM- 1:00 PM	Poster Setup	Quandary Peak
1:00 - 10:00 PM	Poster Viewing	Quandary Peak
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Other Phosphoinositide Kinases Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Grays Peak
	Nullin Divecha, University of Manchester, UK PIP2 Synthesis
	Robin F. Irvine, University of Cambridge, UK Inositide Kinases and their Products - A Matter of Location
	Scott D. Emr, Cornell University, USA Phosphoinositide Signaling and Membrane Trafficking
Following Session is for PI 3-Kinases (X2)
5:00 - 7:00 PM	PI 3-Kinase and Signaling: Non-Class I PI3Ks Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Longs Peak
	Takehiko Sasaki, Akita University School of Medicine, Japan Role for 3-Phosphoinositide Metabolism in vivo
	Jonathan M. Backer, Albert Einstein College Of Medicine, USA Biology and Biochemistry of vps34 Class III PI3K
	Speaker to be Announced,
	Short Talk to be Chosen from Abstracts,
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary Peak
7:30 - 10:00 PM	Poster Session 1 Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Quandary Peak
Tuesday, February 15
7:00 - 8:00 AM	Breakfast	Quandary Peak
8:00 - 11:00 AM	Phosphoinositides in Signaling and Disease Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Grays Peak
	Vojo Deretic, University of New Mexico, USA Phosphoinositides and Autophagy
	Bernard Payrastre, INSERM U.563 BAT B, France Phosphoinositide Signaling Pathways: Promising Role as Builders of Epithelial Cell Polarity
	Peter J. Cullen, University of Bristol, UK Phosphoinositides and the Control of Endosomal Sorting
	Tamas Balla, NICHD, National Institutes of Health, USA Detection and Forced Manipulation of Phosphoinositides in Living Cells
	Short Talk(s) to be Chosen from Abstracts,
Following Session is for PI 3-Kinases (X2)
8:00 - 11:00 AM	Downstream of PI 3-Kinase: Akt, mTOR and Metabolism Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Longs Peak
	Alex Toker, Beth Israel Deaconess Medical Center, USA Akt Isoform Specificity in Breast Cancer Cell Signaling
	Brendan D. Manning, Harvard School of Public Health, USA The TSC-mTOR Pathway Regulates Cellular Metabolism Downstream of PI3K

	Joan S. Brugge, Harvard Medical School, USA PI3K Pathway in Tumor Cell Metabolism and Matrix Control
	Craig B. Thompson, Abramson Family Cancer Center and Research Institute, University of Pennsylvania, USA Talk Title to be Determined
	Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:00 AM- 1:00 PM	Poster Setup	Quandary Peak
1:00 - 10:00 PM	Poster Viewing	Quandary Peak
2:30 - 4:30 PM	Workshop: Novel Aspects of Inositides Signaling	Grays Peak
	Short Talks to be Chosen from Abstracts, ,
Following Workshop is for PI 3-Kinases (X2)
2:30 - 4:30 PM	Workshop 1: Monitoring Phosphoinositide Activation in Signaling and Disease Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011 • Protein-based approaches • Gene expression approaches • Lipid approaches: lipidomics - visualization of phosphoinositides in cells and tissues • Biomarkers	Longs Peak
	* Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA
	Short Talks to be Chosen from Abstracts, ,
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Phosphoinositide Metabolism Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Grays Peak
	Pietro V. De Camilli, Yale University School of Medicine, USA Phosphoinositide Metabolism in Endocytic Membrane Traffic
	Shamshad Cockcroft, University College London, UK Trafficking of Phosphatidylinositol by Phosphatidylinositol Transfer Proteins
	Lois Weisman, University of Michigan, USA PI(3,5)P2 Metabolism and Neurodegeneration
Following Session is for PI 3-Kinases (X2)
5:00 - 7:00 PM	p110delta and p110gamma Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Longs Peak
	Klaus Okkenhaug, Babraham Institute, UK PI3K in T Cell Immunity and Inflammation
	Emilio Hirsch, University of Torino, Italy p1010gamma in Immunity, Inflammation and Cardiac Context
	Neill A. Giese, Calistoga Pharmaceuticals Inc., USA Experience with p110delta Inhibitors in Inflammation and Cancer
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary Peak
7:30 - 10:00 PM	Poster Session 2 Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Quandary Peak
Wednesday, February 16
7:00 - 8:00 AM	Breakfast	Quandary Peak
8:00 - 11:00 AM	Phosphoinositide Phosphatases (Joint) Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Longs/Grays Peak
	Ramon Parsons, Columbia University, USA The Role of PTEN Signaling Perturbations in Cancer and in Targeted Therapy
	Jocelyn Laporte, Institute of Genetics and Molecular and Cellular Biology, France Myotubularins and Associated Neuromuscular Diseases
	Stéphane Schurmans, Universite Libre de Bruxelles, Belgium Phosphoinositide 5- Phosphatases and Human Diseases
	Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center/Harvard Medical School, USA The Role of PTEN in Cellular Senescence
	Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:00 AM- 1:00 PM	Poster Setup	Quandary Peak
1:00 - 10:00 PM	Poster Viewing	Quandary Peak
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Inositol Phosphates Signaling Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Grays Peak
	Lucio Cocco, University of Bologna, Italy Nuclear Inositide Signaling
	Marco Falasca, Barts & The London School of Medicine & Dentistry, UK Role of Phospholipase C in Cell Metastasis
	John Condeelis, Albert Einstein College of Medicine, USA Phosphoinositide Signaling in Actin Polymerization and Invadopod Formation
Following Session is for PI 3-Kinases (X2)
5:00 - 7:00 PM	Therapeutic Strategies in the PI 3-Kinase Pathway Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Longs Peak
	Christian Rommel, Intellikine, Inc., USA Where Are We after a Decade of PI3K Inhibitor Development?
	Jeffrey Adam Engelman, Massachusetts General Hospital, USA Optimizing PI3K Targeting in Cancer, Mechanistic Insights
	Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA PI3K Pathways in Cancer, Mechanistic Insights
	Short Talk to be Chosen from Abstracts,
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary Peak
7:30 - 10:00 PM	Poster Session 3 Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Quandary Peak
Thursday, February 17
7:00 - 8:00 AM	Breakfast	Quandary Peak
8:00 - 11:00 AM	Inositides and Ion Channels Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Grays Peak
	Bertil Hille, University of Washington, USA PIP2 Is a Necessary Cofactor for Ion Channel Function: Biophysical Studies of Phosphoinositides in Living Cells
	Victoria Bolotina, Boston Medical Center, USA Store-Operated Channels
	James W. Putney, Jr., NIEHS, National Institutes of Health, USA STIM1, SOCs and Calcium Oscillations
	Speaker to be Announced,
	Short Talk(s) to be Chosen from Abstracts,
Following Session is for PI 3-Kinases (X2)
8:00 - 11:00 AM	PI 3-Kinase Pathway Inhibitors – Preclinical and Clinical Studies I Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Longs Peak
	Kevan M. Shokat, University of California, San Francisco, USA PI3K Pathway Inhibitors
	Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA A Systems Biology Approach to Monitor the PI3K Pathway
	Sabina C. Cosulich, AstraZeneca, UK Using PI3K Pathway Inhibitors to Unravel the Pathway
	Mika Derynck, Genentech, Inc., USA Clinical Development Strategies of PI3K/mTOR Inhibitors
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Inositol Polyphosphates Signaling Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Grays Peak
	Adolfo Saiardi, University College London, UK Are Inositol Pyrophosphates Signaling Molecules?
	John D. York, Duke University Medical Center, USA Inositol Polyphosphates Kinases
	Susan R. Wente, Vanderbilt University Medical Center, USA Inositol Polyphosphates and Regulation of Gene Expression
Following Session is for PI 3-Kinases (X2)
5:00 - 7:00 PM	PI 3-Kinase Pathway Inhibitors – Clinical Studies II Registered attendees for this meeting can view Abstracts for this session starting on 01/13/2011	Longs Peak
	Pearl S. Huang, Merck & Co., Inc., USA Using Biomarker Tools to Position PI3K Pathway Inhibitors in Clinical Studies
	Jose Baselga, Vall d'Hebron University Hospital, Spain Ongoing Clinical Studies with PI3K Inhibitors in Cancer Patients
	Barbara L. Weber, Novartis, USA Experience with PI3K Pathway Inhibitors in the Clinic
	Short Talk to be Chosen from Abstracts,
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary Peak
8:00 - 11:00 PM	Entertainment	Quandary Peak
Friday, February 18
	Departure
*=Session Chair †=Speaker invited, not yet responded.

We gratefully acknowledge support for this conference from:

We gratefully acknowledge the generous grants for this conference provided by:

National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Aging (NIA)
Grant No. 5R13DK084688-02

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We gratefully acknowledge the organizations that provide Keystone Symposia with additional support, such as marketing and advertising...

Click here to view these companies

Phosphoinositide and inositol phosphates interact with and modulate the recruitment and activation of key regulatory proteins and in doing so control diverse functions including cell growth and proliferation, apoptosis, cytoskeletal dynamics, insulin action, vesicle trafficking and nuclear function. Initially, inositide signaling was limited to the PLC pathway; however, it is now clear that all the seven phosphoinositides and more than 30 different inositol phosphates likely have specific signaling functions. Moreover there is a growing list of proteins that are regulated by inositol signaling. This has raised the question as to how inositol signaling can control diverse processes and yet maintain signaling specificity. Controlling the levels of inositol signaling molecules and their subcellular compartmentalisation is likely to be critical. This meeting will bring together scientists from different backgrounds to discuss how understanding inositol signaling may be used to target complex human diseases that manifest themselves when inositol signaling is deregulated.

Inositide Signaling in Pharmacology and Disease (X1)